Drugs / Oral testosterone undecanoate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01403116 | Jul 2011 → Sep 2013 | hypogonadism, male | Clarus Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oral testosterone undecanoate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01403116 ↗ |
| Known as | JATENZO | “oral testosterone undecanoate (oral TU; JATENZO)” PMID 36272969 ↗ Oct 2022 |
| Route | Oral | “two 100 mg capsules, orally, twice a day” NCT01403116 ↗ |